Search Results
Dec 08, 2025, 12:00 ET Castlight Health Partners With Noom to Expand Access to Personalized Programs for Weight and Chronic Conditions
Castlight's personalized health benefits platform provides seamless access to Noom's health programs including diabetes, GLP-1s and weight support for employers and health plans.SEATTLE and NEW YORK, Dec.
More news about: Castlight Health
Dec 08, 2025, 08:03 ET Grace and Molecule.one to Transform Peptide Building Block Synthesis with AI and Automation
supply chain bottleneck in peptide components—the building blocks essential for manufacturing therapeutics, including the rapidly expanding GLP-1 treatments for weight loss and diabetes. With strong demand for metabolic-disease peptides, the global market is expected to more than double by
More news about: W. R. Grace
Dec 08, 2025, 04:40 ET Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
1672, "Ascletis") announces today positive topline results in its 13-week Phase II study evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist for the treatment of obesity (NCT07002905)
More news about: Ascletis Pharma Inc.
Dec 08, 2025, 04:40 ET 歌禮口服小分子GLP-1藥物ASC30在肥胖或超重受試者中進行的美國13周II期研究顯示經安慰劑校正後的體重下降高達7.7%，且胃腸道耐受性更佳
View original content:https://www.prnewswire.com/apac/zh/news-releases/glp-1asc3013ii7-7-302635192.htmlSOURCE 歌禮製藥有限公司
More news about: 歌禮製藥有限公司
Dec 06, 2025, 17:25 ET MENU - ORDER AI Announces Global Expansion with New Multilingual Capabilities, Supporting WHO Guidance on Dietary Needs for GLP-1 Users
MENU – ORDER AI, the first real-time GLP-1 dining companion designed to guide users toward High-protein and GLP-1 friendly meal choices, announced that the app now supports a growing international audience with multilingual capabilities.
More news about: MENU - ORDER AI
Dec 06, 2025, 17:15 ET MENU - ORDER AI Announces Global Expansion with New Multilingual Capabilities, Supporting WHO Guidance on Dietary Needs for GLP-1 Users
MENU – ORDER AI, the first real-time GLP-1 dining companion designed to guide users toward High-protein and GLP-1 friendly meal choices, announced that the app now supports a growing international audience with multilingual
More news about: MENU - ORDER AI
Dec 05, 2025, 06:12 ET November in Review: 10 Top Health Press Releases
Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and VomitingThis study, which pre-treated patients with either tradipitant or placebo before administering a 1 mg
More news about: PR Newswire
Dec 05, 2025, 06:02 ET 13 Top Press Releases from November
Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting"Tradipitant's effect in reducing nausea and vomiting could significantly improve GLP-1 agonist adherence enabling more people to receive the full therapeutic benefit,"
More news about: PR Newswire
Dec 05, 2025, 01:25 ET 康霈出席第四季法人論壇：揭示CBL-514聯用瘦瘦針最新動物數據 展現四大關鍵優勢、竇根氏症二期成果將獲登國際權威期刊JAAD
更佳的體重維持效果：從根本改善瘦瘦針停藥後復胖之市場痛點GLP-1 類藥物雖能有效降低體重，但僅能「縮小」脂肪細胞體積，並未減少脂肪細胞的「數量」。國外研究指出，即使成功減重，脂肪細胞仍保留「肥胖記憶」，使得減重後的脂肪細胞更容易吸收糖分及脂肪，因脂肪細胞會「記住過去胖的狀態」，進而導致一旦停藥後身體迅速復胖。OI23動物實驗亦觀察到相同現象： GLP-1R停藥三週後，體重回升幅度高達 55.9%。相比之下，CBL-514 與 GLP-1R聯合療法於停藥後僅回升 25.2%，體重維持效果提升 2.2 倍。CBL-514
More news about: 康霈生技
Dec 04, 2025, 16:21 ET FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
clinical development for a variety of indications, including gastroparesis, motion sickness, and the prevention of nausea and vomiting induced by GLP-1 receptor agonists. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSVarious statements in this press release, including,
More news about: Vanda Pharmaceuticals Inc.
Dec 04, 2025, 10:01 ET New Data from Semaglutide Trials Provides Critical Insights to Guide Next Generation of Therapies Targeting Alzheimer's Pathobiology
Exploring GLP-1 drugs as preventive therapy may still hold promise within broader strategy targeting Alzheimer's pathways beyond amyloid, ADDF notesSAN DIEGO, Dec. 4, 2025
More news about: Alzheimer's Drug Discovery Foundation
Dec 04, 2025, 04:42 ET Generic Injectables Market Dominated by Hospital Pharmacies with 61.23% Share as Online Pharmacies Surge at 18.06% CAGR Through 2030, Reports Mordor Intelligence
Anti-diabetic Drugs Market: The injectable anti-diabetic drugs market report is segmented by drug class (insulin [basal/long-acting], GLP-1 receptor agonists), diabetes type (type-1 diabetes, type-2 diabetes), distribution channel (hospital pharmacies, retail pharmacies, online pharmacies),
More news about: Mordor Intelligence Private Limited
Dec 03, 2025, 16:56 ET Tendências para 2026: esses são os procedimentos estéticos que estarão em alta para o ano que vem
31. Nikolis A, et al. J Drugs Dermatol. 2024 23(4):255-261.32. Humphrey CD, et al. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719-721 Sobre a Galderma A Galderma é uma
More news about: Galderma
Dec 03, 2025, 14:00 ET Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program
(Therapeutic for Alzheimer's Disease) – Advancing Through GLP and PK Development.HT-ALZ continues to deliver supportive data across absorption, distribution, and neuroinflammatory pathways.Recent highlights:GLP studies underway with positive PK, biodistribution,
More news about: Hoth Therapeutics, Inc.
Dec 03, 2025, 10:00 ET Introducing Arctic Pur: Belly Soothing Freezer Pops
when life gets a little wobbly. Whether its expectant moms navigating the ups and downs of pregnancy, kids recovering from a bug, GLP-1 users adjusting to their new wellness routines, or anyone who's just having "one of those queasy days," Arctic Pur is here with something
More news about: Arctic Pur, LLC
Dec 03, 2025, 09:31 ET Rising Health Costs Force Even Insured Americans to Skip Preventive Care
they cannot afford to pay an unexpected $500 out-of-pocket medical bill.The introduction of high-cost medications, including GLP-1 drugs for diabetes and weight management, is adding more pressure. Many adults who could benefit from these treatments face steep out-of-pocket
More news about: Nationwide
Dec 03, 2025, 09:05 ET FMI Reports Strong 11.7% CAGR Growth Outlook for the GLP-1 Receptor Agonist Market Through 2035
ReportFMI's GLP-1 Receptor Agonist Market Report covers:Top GLP-1 drugs globallyDemand for oral GLP-1 therapiesComparison between Semaglutide and OzempicGLP-1 mechanisms, GLP-1 vs. GLP-2 studiesMarket
More news about: Future Market Insights, Inc.
Dec 03, 2025, 09:00 ET Open Enrollment Snapshot: 77% of Americans Are Pleased with Their Health Insurance Options for 2026
beneficiaries.59% of Americans support the administration's plan to make GLP-1 drugs broadly available for weight loss at discounted prices.33% of Americans intend to take a GLP-1 drug when discounted pricing takes effect; among these, 68% are willing to pay $100
More news about: eHealth, Inc.
Dec 03, 2025, 08:00 ET Avance Biosciences Launches Potency & Cell-Based Assay Center in Houston
evaluating the biological activity of complex therapeutics.About Avance BiosciencesAvance Biosciences is a leading CRO providing GLP-, GMP-, and CLIA-compliant testing services to support drug, biologics, and cell/gene therapy development. With expertise in molecular biology, sequencing,
More news about: Avance Biosciences, Inc.
Dec 02, 2025, 08:45 ET MetaVia Inc. Announces 1-for-11 Reverse Stock Split
peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In
More news about: MetaVia Inc.
Dec 01, 2025, 09:01 ET New York City IV Therapy Leader IVDRIPS Hosts Sold-Out Wellness Event in Midtown Manhattan, Launching Luxury Drip Party Services for Corporate and Private Celebrations
medical weight loss solutions, and GLP-1 therapies. The practice has become a trusted leader in personalized weight management, offering science-backed support for patients using medications
More news about: IVDRIPS
Nov 30, 2025, 05:15 ET Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
(POTENT). ASC37, a GLP-1R, GIPR, and GCGR triple peptide agonist, was discovered and optimized in-house utilizing Ascletis' Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD). ASC37 in vitro activity was approximately 5-, 4-, and 4-fold more potent than retatrutide for GLP-1R, GIPR and
More news about: Ascletis Pharma Inc.
Nov 30, 2025, 05:15 ET 歌禮選定其首款口服GLP-1R/GIPR/GCGR三靶點激動劑多肽ASC37進行臨床開發
[1] GLP-1R：胰高血糖素樣肽-1受體，GIPR：葡萄糖依賴性促胰島素多肽受體，GCGR：胰高血糖素受體[2] 絕對口服生物利用度：指與靜脈給藥相比，相同藥物在以口服方式給藥後進入全身循環（血液）的劑量百分比
More news about: 歌禮製藥有限公司
Nov 28, 2025, 09:55 ET eDrugstore.com Releases Black Friday-Cyber Week Pricing Update for Its Health and Wellness Portfolio
formula that supports skin rejuvenation.Sermorelin, a therapy supporting hormone balance and testosterone regulation.GLP-1 compounds, used under medical supervision for weight management.Peak Body nutraceuticals, a new product line formulated to enhance
More news about: eDrugstore.com
Nov 28, 2025, 07:00 ET Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
clinical development for a variety of indications, including gastroparesis, motion sickness, and the prevention of nausea and vomiting induced by GLP-1 receptor agonists.CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSVarious statements in this press release, including,
More news about: Vanda Pharmaceuticals Inc.